Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsReiterationPrice Target
Truist Securities analyst Gregory Renza reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $59 to $57.
Truist Securities analyst Gregory Renza reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $59 to $57.